News

Sygnis grabs X-Pol
Enlarge image

BusinessSpainGermany

Sygnis grabs X-Pol

20.07.2012 - Sygnis Pharma is acquiring Spanish sequencing technology specialist X-Pol Biotech S.L., a subsidiary of Genetrix Life Sciences A.B. The German biotech said the move is a step forward into the molecular diagnostics business.

Under terms of the proposed deal Sygnis will take 100% ownership of X-Pol through a capital increase against contribution in kind. Once the transaction has been completed, existing X-Pol shareholders will hold 77.5% of all shares in Sygnis. The proposed terms of the deal have been approved by both firms’ executive and supervisory boards.

Madrid-based X-Pol was founded in 2008 to develop tools and technologies for DNA amplification and sequencing. Currently 84% owned by biotech incubator Genetrix. The lead product, Qualiphi polymerase, was recently licensed to Qiagen. X-Pol claims its DNA polymerases demonstrate unique properties that boost the performance of DNA amplification, and can be applied for a wide range of applications in DNA amplification, repair, sequencing, and genetic modification.

Sygnis said the acquisition of X-Pol will represent a major shift in its business focus. To date, the firm has specialised in the development of therapies for central nervous system disorders. Its pipeline was headed by a granulocyte colony–stimulating factor candidate filgrastim (AX200), which was evaluated in a Phase II trial as a treatment for ischemic stroke. However, the study data, reported in December 2011, failed to show any benefits of therapy using AX200. Sygnis confirmed in February that it was looking at M&A opportunities or other financing options. The Heidelberg-based firm said the aim will be to build the X-Pol DNA sequencing business and related activities within the field of molecular diagnostics. “The company will have an entirely new focus and business and will provide a lower risk profile with the near-term visibility of revenues and profitability”, Sygnis-CFO Peter Willinger said.

http://www.european-biotechnology-news.com/news/news/2012-03/sygnis-grabs-x-pol.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%

FLOP

  • 4SC (D)2.59 EUR-20.31%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-4.55%
  • FORMYCON (D)20.15 EUR-4.37%

TOP

  • GALAPAGOS (B)51.86 EUR30.6%
  • NICOX (F)11.00 EUR26.0%
  • GENMAB (DK)1177.00 DKK21.2%

FLOP

  • 4SC (D)2.59 EUR-24.5%
  • MOBERG PHARMA (S)38.00 SEK-23.1%
  • BIONOR PHARMA (N)0.68 NOK-20.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)30.60 SEK1913.2%
  • NICOX (F)11.00 EUR485.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.1%
  • BB BIOTECH (D)44.03 EUR-84.7%
  • BIOTEST (D)17.15 EUR-78.0%

No liability assumed, Date: 27.05.2016